Publication: The Performance of Modified Swede Colposcopic Index to Predict High Grade Cervical Intraepithelial Neoplasia and Cervical Cancer in the Real Clinical Practice, an External Validation Study
0
0
Issued Date
2025-08-01
Resource Type
eISSN
2476762X
Scopus ID
2-s2.0-105015262977
Pubmed ID
40849711
Journal Title
Asian Pacific Journal of Cancer Prevention APJCP
Volume
26
Issue
8
Start Page
2947
End Page
2952
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Cancer Prevention APJCP Vol.26 No.8 (2025) , 2947-2952
Suggested Citation
Klangprapan N., Rodpenpear N. The Performance of Modified Swede Colposcopic Index to Predict High Grade Cervical Intraepithelial Neoplasia and Cervical Cancer in the Real Clinical Practice, an External Validation Study. Asian Pacific Journal of Cancer Prevention APJCP Vol.26 No.8 (2025) , 2947-2952. 2952. doi:10.31557/APJCP.2025.26.8.2947 Retrieved from: https://hdl.handle.net/20.500.14740/50482
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
OBJECTIVE: The primary objective is to examine the external validity of the modified Swede colposcopic index (MSCI) for predicting cervical intraepithelial neoplasia grade 2-3, including cancer (CIN2+), and to evaluate inter-rater and intra-rater reliability as a secondary objective in women with abnormal cervical cancer screening. METHODS: We conducted a prospective study to predict CIN2+ in women aged 25-65 years with abnormal cervical cancer screening results (atypical squamous cells of undetermined significance (ASC-US) or higher and/or high-risk HPV infection). All participants were previously undiagnosed with CIN2+. We evaluated the effectiveness of MSCI in detecting CIN2+ using sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). RESULTS: A total of 118 women were included in this study. Gynecologic oncologists using the MSCI achieved a sensitivity of 46.9%, specificity of 87.2%, PPV of 57.7%, NPV of 81.5%, and accuracy of 76.27%. Inter-rater reliability for the MSCI was good (ICC=0.77, 95%confidence interval=0.67-0.84), and intra-rater reliability was excellent (ICC=0.98, 95%confidence interval =0.97-0.99). CONCLUSION: In a real-world clinical setting, studies have demonstrated that MSCI exhibits high specificity while maintaining acceptable sensitivity.